Adaptimmune Therapeutics plc (NASDAQ:ADAP) Receives $6.12 Average Target Price from Brokerages

Shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP – Get Rating) have earned an average rating of “Moderate Buy” from the six research firms that are currently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1 […]

Related Keywords

United Kingdom ,Helena Katrina Tayton Martin ,Susquehanna International Group ,Virtu Financial ,Sorce Advisory ,Adaptimmune Therapeutics Plc ,Nasdaq ,Garnier Co ,Ef Hutton Acquisition Co ,Adaptimmune Therapeutics ,Get Rating ,Marketbeat Ratings ,Sigma Investments ,International Group ,Therapeutics Plc ,James Julian Noble ,Adaptimmune Therapeutics Daily ,